IonOpticks launches Aurora Series® 5 and new CoreJetTM emitter technology, advancing robust nano-LC for routine proteomics research.
IonOpticks launched its Aurora Series 5 and CoreJet emitter technology. This release aims to improve nano-LC robustness for routine proteomics research. The new CoreJet integrated emitter and redesigned nanoZero union are designed to lower cost per sample. Researchers will see no compromise in depth or sensitivity. The company is based in Melbourne, Australia.
IonOpticks' new CoreJet emitter technology targets a core problem in proteomics: sample robustness. The Aurora Series 5 promises a step-change in reliability. This matters for labs running high volumes of samples, as it directly impacts operational costs and data consistency. The focus on "routine research" suggests a play for broader market adoption beyond specialized applications.
For Asia, this could accelerate proteomics adoption in research institutions. Countries like South Korea and Singapore heavily invest in biotech infrastructure. They need reliable, cost-effective tools for large-scale studies. IonOpticks' move could make advanced protein analysis more accessible for these regional players.
The thing to watch is how quickly CoreJet gains traction against established competitors in Asia. Its success depends on real-world performance data and competitive pricing. If it delivers on its promise of lower cost per sample, it will challenge existing market leaders by late 2027.
Related reading
6 stories
HSBC Gives Wealthy Singapore Clients Access to Private Markets
OpenAI said to explore pre-IPO funding at $1.2T valuation
Samsung Starts Trial Production of Tesla AI Chips in Texas
Moody’s takes minority stake in Phil Ratings to deepen PH debt market
European shares hit three-month low as oil spike revives inflation and rate worries
